Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a standard treatment for relapsed or refractory B-cell non-Hodgkin lymphomas. Long-term results and curative potential remain uncertain. We ...

A Northwestern Medicine study has uncovered new insights that may aid in understanding and potentially treating one of the most common and aggressive forms of non-Hodgkin lymphoma, according to ...

Much of the challenge in developing cancer therapies is determining methods to improve the effectiveness of the immune system’s ability to identify and kill cancer cells. While therapies like CAR T ...

Scientists at École Polytechnique Fédérale Lausanne (EPFL), and at UNIL-CHUV, University Hospital Lausanne (CHUV) and University of Lausanne (UNIL) have developed a computational method to create ...

Cell surface proteins are essential regulators of cell communication, mediating immune activation, cell adhesion, receptor ...